SCHEMBL30345360

SCHEMBL30345360

COc1cc(Br)cc(C(=O)O)c1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.54
LCK P06239 1/20 0.53
FYN P06241 1/20 0.53
PIM1 P11309 1/20 0.46
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 3/20 0.46
HPGD P15428 2/20 0.46
AKR1C4 P17516 1/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
AKR1C1 Q04828 1/20 0.43
HTT P42858 2/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
RAB9A P51151 1/20 0.42
POLB P06746 1/20 0.41
ERN1 O75460 1/20 0.41
CFD P00746 2/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20396821 1.00 HSD17B10 (0.54) HSD17B10LCKFYNPIM1ALDH1A1
SCHEMBL20397117 0.84 KDM4E (0.46) HSD17B10LCKFYNPIM1ALDH1A1
SCHEMBL18700929 0.81 LCK (0.47) HSD17B10LCKFYNALDH1A1KDM4E
SCHEMBL16898580 0.81 TSHR (0.57) HSD17B10KDM4EAKR1C4AKR1C3AKR1C2
SCHEMBL16098563 0.80 AKR1C3 (0.56) HSD17B10LCKFYNKDM4EHPGD
SCHEMBL1188761 0.80 HSD17B10 (0.71) HSD17B10LCKFYNPIM1ALDH1A1
SCHEMBL20076078 0.80 HSD17B10 (0.56) HSD17B10LCKFYNPIM1ALDH1A1
SCHEMBL4404488 0.80 KDM4E (0.47) LCKFYNALDH1A1KDM4EHPGD
SCHEMBL22831957 0.80 ALDH1A1 (0.46) LCKFYNALDH1A1KDM4EHPGD
SCHEMBL1894382 0.80 AKR1C3 (0.58) HSD17B10LCKFYNPIM1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630563-B2 Macrocyclic RIP2-kinase inhibitors ONCODESIGN S.A. (FR) 2026-05-19 US disclosed
US-20260125396-A1 MACROCYCLIC RIP2-KINASE INHIBITORS ONCODESIGN S.A. (FR) 2026-05-07 US disclosed
EP-4518974-A1 IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS Interline Therapeutics, Inc. (US) 2025-03-12 EP disclosed
WO-2024254537-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS, INC. (US) 2024-12-12 WO disclosed
WO-2023239941-A1 IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS INTERLINE THERAPEUTICS INC. (US) 2023-12-14 WO disclosed
US-20230126352-A1 MACROCYCLIC RIP2-KINASE INHIBITORS ONCODESIGN SA (FR) 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125396-A1 MACROCYCLIC RIP2-KINASE INHIBITORS RIPK1, RIPK2, RIPK4 HSD17B10 1705/4885LCK 2042/4885FYN 3560/4885
US-12630563-B2 Macrocyclic RIP2-kinase inhibitors RIPK1, RIPK2, RIPK3 HSD17B10 2031/4885LCK 2432/4885FYN 3209/4885
US-20230126352-A1 MACROCYCLIC RIP2-KINASE INHIBITORS RIPK2, RIPK1, RIPK3 HSD17B10 3545/4885LCK 1234/4885FYN 2703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.